|
|
|
|
| LEADER |
01891nam a22003375i 4500 |
| 001 |
000281459 |
| 005 |
20211110154947.0 |
| 007 |
cr nn 008mamaa |
| 008 |
100301s2005 sz | s |||| 0|eng d |
| 020 |
|
|
|a 9783764373054
|
| 024 |
7 |
|
|a 10.1007/b137043
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Drugs for Relapse Prevention of Alcoholism /
|c edited by Rainer Spanagel, Karl F. Mann.
|
| 250 |
|
|
|a 1st ed. 2005.
|
| 260 |
# |
# |
|a Basel :
|b Birkhäuser Basel :
|b Imprint: Birkhäuser,
|c 2005.
|
| 300 |
|
|
|a XII, 244 p. :
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Milestones in Drug Therapy,
|
| 505 |
0 |
|
|a History of prevention of relapse -- How to measure relapse in animals -- How to measure relapse in humans -- Disulfiram (Antabuse®): the first medication to stop drinking -- Naltrexone: preclinical data -- Naltrexone: clinical data -- Acamprosate: preclinical data -- Acamprosate: clinical data -- Serotonergic compounds: preclinical data -- Serotonergic compounds: clinical data -- Opioidergic compounds: preclinical data -- Second generation opioidergic compounds: clinical data -- Dopaminergic compounds: preclinical data -- Dopaminergic compounds: clinical data -- Baclofen: preclinical data -- Baclofen: clinical data -- Cannabinoid receptor antagonists: a perspective -- Neuropeptide Y antagonists: a perspective -- Glutamatergic compounds: a perspective -- Future perspectives on relapse prevention.
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
|
0 |
|a Neurosciences.
|
| 650 |
|
0 |
|a Psychiatry.
|
| 650 |
1 |
4 |
|a Pharmacology/Toxicology.
|
| 650 |
2 |
4 |
|a Neurosciences.
|
| 650 |
2 |
4 |
|a Psychiatry.
|
| 700 |
1 |
|
|a Spanagel, Rainer.
|e editor.
|
| 700 |
1 |
|
|a Mann, Karl F.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|